News

The safe use of the CredibleMeds® lists of QT-prolonging medications requires being aware of any changes that are mede to the lists. Therefore, we wish to inform you of the following changes.

Changes made to classification of some antidepressants

Donepezil and cilostazol added to the list of of drugs with Known Risk of TdP. Torsemide added to the list of drugs with Conditional Risk of TdP. Atomoxetine added to the list of drugs with Possible Risk of TdP.

Fosphenytoin removed from two lists, Ciprofloxacin and Fluconazole moved to Known Risk of TdP list, and Propofol added to the list of drugs with Known Risk of TdP.

Everyone in DC knows that the FDA Commissioner’s job is the most difficult appointed position in government.

This one-day CME course organized by Dr. Glenn Fishman and Dr. Silvia Priori will focus on inherited arrhythmogenic diseases that can cause sudden arrhythmic death. A panel of internationally recognized experts will cover updates on long QT syndrome (LQTS), Brugada syndrome (BrS), catecholaminergic polymorphic ventricular tachycardia (CPVT), and arrhythmogenic cardiomyopathy (ARVC).

Hydroxychloroquine added and Trimethoprim Sulfamethoxazole moved on lists

Update for Online Version of My Medicines Forms

Hydroxyzine and metoclopramide were added to the list of drugs that cause Torsades de Pointes (TdP) under certain clinical conditions.

TUCSON, AZ – CredibleMeds®, the internationally recognized authority on drug safety, has been awarded a three-year contract from the Safe Use Initiative of the U.S. Food and Drug Administration (FDA) to further their mutual goal of promoting and facilitating the safe use of medicines. Several thousand people in the US die each year from taking certain commonly prescribed antibiotics that have heart toxicity, when safer alternatives could be identified.